FASN and metabolic dysfunction-associated steatotic liver disease: TVB-2640, a highly potent and selective FASN inhibitor, was designed to reduce hepatic fat in nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (34, 35).